Olanzapine for Injection (Intramuscular)

Abstract

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. With a subscription, the monographs are sent to you in print and CD ROM forms and are available online. Monographs can be customized to meet the needs of your facility. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X.

Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800-322-4349. The August 2004 monograph topics are lansoprazole injection, trospium chloride, tinidazole, natalizumab, and rubitecan. The DUE is on injectable proton-pump inhibitors.

Get full access to this article

View all access options for this article.

References

Zyprexa, Zyprexa Zydis, and Zyprexa IntraMuscular [prescribing information]. Eli Lilly and Company; March 29, 2004.

Meehan

A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol. 2001; 21: 389–97.

Bergstrom

Examination of the safety, tolerance, and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects [abstract]. Schizophrenia Res. 1999; 36(1-3): 305–6.

Wright

A preliminary study of the safety, efficacy, and pharmacokinetics of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophrenia Res. 1999; 36(1-3): 318.

Dubitsky

G.M.

Draft review and evaluation of clinical data NDA # 21-253. Center for Drug Evaluation and Research. Food and Drug Administration. www.fda.gov. December 20, 2000.

Eli Lilly and Company. Briefing document for Zyprexa intramuscular (olanzapine for injection). FDA Psychopharmacological Drugs Advisory Committee (February 14, 2001). www.fda.gov. January 11, 2001.

Wright

Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001; 158: 1149–51.

Battaglia

Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003; 21: 192–8.

Wright

Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: Antipsychotic efficacy and extrapyramidal safety during the first 24-hours of treatment. Can J Psychiatry. 2003; 48: 716–21.

10.

Wright

Olanzapine versus haloperidol in transitioning from intramuscular (IM) to oral therapy [abstract]. Pharmacotherapy. 2001; 21: 1292–3.

11.

Wright

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin Ther. 2003; 25: 1420–8.

12.

Jones

The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry. 2001; 62(suppl 1): 22–4.

13.

Breier

A double-blind dose response study comparing intramuscular (IM) olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients [abstract]. Biol Psychiatry. 2001; 49: 121S.

14.

Wright

A double-blind dose response study comparing intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients [abstract]. Schizophrenia Res. 2001; 49(1-2, suppl):250–1.

15.

Breier

A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002; 59: 441–8.

16.

Wright

Safety and efficacy of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophrenia Res. 1999; 36(1-3): 318.

17.

Meehan

K.M.

A double-blind, placebo-controlled study of intramuscular (IM) olanzapine and IM lorazepam in acutely agitated patients with dementia [abstract]. Biol Psychiatry. 2001; 49: 55S.

18.

Meehan

K.M.

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002; 26: 494–504.

19.

Lindborg

S.R.

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003; 119: 113–23.